Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Tiziana Pharma
Tiziana Pharma
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Tiziana announces positive PET scan results with intranasal Foralumab in patients with na-SPMS
Five out of six patients in FDA authorised expanded access programme are showing a qualitative reduction in microglia activation (a key biomarker being observed)
Manufacturing
Tiziana Life Sciences appoints Chief Development Officer
William A. Clementi will take up the role of Chief Development Officer, which will become effective as of September 1 2023
Research & Development
Tiziana develops novel treatment for COVID-19 patients using anti-interleukin-6-receptor mAbs
Company has filed patent application in support of treatment of COVID-19 utilizing anti-il6r via inhaled delivery
Research & Development
Tiziana strengthens unique research focus by appointing Dr Kunwar Shailubhai CEO
Pharmaceutical
Tiziana Life Sciences appoints Arun Sanyal to its Scientific Advisory Board
Arun Sanyal is a professor and a key opinion leader in liver diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Ingredients
Tiziana Life Sciences in-licenses NI-1201, a fully human anti-IL-6R monoclonal antibody
Exclusive worldwide license expands therapeutic pipeline in key immunological areas
Research & Development
Tiziana acquires bio-repository from Shardna and establishes Sardinian subsidiary LonGevia
Aims to further enhance and develop its portfolio using data from the biobank and genomics research
Subscribe now